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Abstract: Nanotechnology-based drug delivery systems are in constant development and, therefore, it is of great 
importance to have rapid, efficient and accurate analytical methodology to quantify the encapsulated drugs. Here, simple 
and fast methods, by reversed-phase liquid chromatography (RP-LC) and UV spectrophotometry, were developed and 
validated for the determination of methotrexate (MTX) in pH-sensitive chitosan nanoparticles (CS-NPs). NPs were 
prepared using a modified ionotropic complexation process, in which was included a surfactant derived from N?,N?-
dioctanoyl lysine with an inorganic sodium counterion. The RP-LC method was carried out on a Waters XBridgeTM C18 
column (250 mm x 4.6 mm I.D., 5μm), with mobile phase consisted of potassium phosphate buffer (0.05 M, pH 3.2): 
acetonitrile (86:14, v/v), and UV detection set at 303 nm. The analyses of MTX content by the UV method were also 
accomplished at 303 nm, using 0.1 M sodium hydroxide as diluent. The measurements were linearly correlated with 
concentration for both methods in the 1 - 30 μg/mL range (r > 0.9999). The specificity tests showed that there was no 
interference of the NP components on the quantitative analyses. Precision (repeatability and intermediate precision) was 
demonstrated by a relative standard deviation lower than 1.5%, whereas the accuracy was assessed by the recovery of 
MTX from sample matrices, given mean value of ~99%. The proposed methods were applied for the analyses of MTX in 
different batches of NPs, and the results showed non-significant differences (p > 0.05) between the values obtained with 
both methodologies. Moreover, the RP-LC method was successfully used to determine the drug entrapment efficiency, 
and to quantify MTX during in vitro release assays and photolytic degradation studies. In conclusion, the validated 
methods are suitable to assay MTX in pH-sensitive CS-NPs without any interference from the polymer or surfactant. 
Keywords: Chitosan nanoparticles, methotrexate, lysine-based surfactant, reversed-phase liquid chromatography, 
UV spectrophotometry, validation. 
1. INTRODUCTION 
Methotrexate (MTX, 2,4-diamino-N10-methyl-folic 
acid) is a dihydrofolate reductase (DHFR) inhibitor that 
is well established for the treatment of solid tumors and 
leukemias [1]. It is an antimetabolite drug that acts as 
an antagonist of folic acid, which is necessary for DNA 
synthesis [2]. Despite the current use of MTX to treat 
many types of cancer, its administration has the 
potential to cause severe side effects, including 
neurologic toxicity, renal failure and mucositis [3]. 
Therefore, it is of great importance the development of 
new approaches with higher specificity and 
effectiveness to deliver the chemotherapeutic agent to 
the tumor. Nanotechnology-based systems, with 
improved physicochemical properties, might appear as 
a promising tool to overcome the shortcomings  
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associated with conventional drug delivery strategies 
[4,5]. More specifically, polymeric nanoparticles (NPs) 
with pH-sensitive properties might achieve greater 
antitumor activity due to their specificity for the acidic 
extracellular space of tumors [6].  
Chitosan (CS) is derived from natural sources and 
due to its biocompatibility, biodegradability and non-
toxicity has been considered a harmless polymer to be 
used in the development of nanocarriers [7]. CS NPs 
have been investigated as a promising colloidal drug 
carrier for targeted delivery in cancer therapy [8-10]. 
CALVO et al. [11] firstly described the procedure for 
preparation of CS-based NPs by the ionotropic gelation 
method, where the natural polymer CS was dissolved 
in acetic acid (1% solution in water) and then a solution 
of the polyanion tripolyphosphate (TPP) was added 
dropwise under high stirring speed.  
Several LC (Liquid chromatography) methods have 
been developed to determine MTX in different matrices 
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and with various purposes, ranging from quality control 
to clinical pharmacokinetics and therapeutic drug 
monitoring [1,12,13]. Among these methods, a variety 
of chromatographic conditions have been described, 
including acidic or neutral mobile phase and UV, 
fluorimetry or mass spectrometry detection [1,14,15]. 
Likewise, standard analytical methodologies based on 
LC with UV detection are described in the main 
Pharmacopoeias for MTX as raw material [16-18] or 
injectable preparation [17,18]. However, these methods 
are suitable for pharmaceutical products without 
complex matrices, and not for formulations based on 
polymers and surfactants, as are the NPs. In the field 
of nanotechnology-based products, there is only one 
LC method reported in the literature, which comprises 
the determination of MTX entrapment efficiency in poly 
(DL-lactic acid) nanocapsules [19].  
Therefore, the aim of the present work was to 
develop and validate a specific and sensitive RP-LC 
method, and also a simple and cost-effective UV 
spectrophotometric method, for the quantitative 
analysis of MTX in pH-sensitive CS-based NPs. Both 
methods were successfully applied to assess MTX 
content in different batches of NPs, while the LC 
procedure was also used to determine the drug 
entrapment efficiency, the MTX in vitro release profile 
and the photolytic degradation kinetics of the 
encapsulated drug.  
2. EXPERIMENTAL 
2.1. Chemical and Reagents 
Methotrexate (MTX, state purity 100.1 %; batch no 
1504478) was purchased from SM Empreendimentos 
Farmacêuticos Ltda. (São Paulo, SP, Brazil). Chitosan 
(CS) of low molecular weight (deacetylation degree, 
75-85%; viscosity, 20-300 cP according to the manu-
facturer’s data sheet), pentasodium tripolyphosphate 
(TPP) and dimethyl sulfoxide (DMSO) were obtained 
from Sigma-Aldrich (St. Louis, MO, USA). HPLC-grade 
acetonitrile was purchased from Tedia (Fairfield, USA) 
and potassium phosphate from Merck (Darmstadt, 
Germany). All chemicals used were of pharmaceutical 
or special analytical grade. For all of the analyses, 
ultrapure water was purified using a Mega RO/UP - 
Mega Purity system. 
2.2. Apparatus and Analytical Conditions 
The RP-LC method was performed on a Shimadzu 
LC system (Shimadzu, Kyoto, Japan) equipped with an 
SCL-10AVP system controller, a LC-10 ADVP pump, a 
manual sample valve injector with a 20 ?L loop and an 
SPD-10AVP ultraviolet (UV) detector. A Shimadzu Class 
VP V 6.14 software program was used for data 
acquisition and analysis of chromatograms. In addition, 
the evaluation of peak purity during the specificity test 
was performed on a Shimadzu LC system (Shimadzu, 
Kyoto, Japan) equipped with a SPD-M20A photodiode 
array (PDA) detector. The analyses of MTX were 
carried out on a reversed-phase Waters (Milford, MA, 
USA) XBridgeTM C18 column (250 mm x 4.6 mm I.D., 
with a particle size of 5 μm and pore size of 110 Å). 
The LC system was operated isocratically, at room 
temperature, using a mobile phase consisted of 
potassium phosphate buffer (0.05 M, pH 3.2) and 
acetonitrile (86:14, v/v), which was filtered through a 
0.45 ?m membrane filter (Millipore) and run at a flow 
rate of 1.0 mL/min. The UV detection was set at 303 
nm and the injection volume was 20 ?L. Before 
injections, the column was equilibrated for at least 20 
min with mobile phase flowing through the system, and 
each sample was filtered through a 0.45-μm 
membrane. 
The UV spectrophotometric experiments were 
performed on a double-beam UV-VIS spectrophoto-
meter (Shimadzu, Japan), model UV–1800, with a fixed 
slit width (2 nm) and a 10 mm quartz cell was used to 
obtain spectrum and absorbance measurements. The 
wavelength was set at 303 nm and the diluent chose 
was 0.1 M sodium hydroxide (NaOH). 
2.3. Preparation of Reference Substance Solution 
The reference stock solution was prepared by 
dissolving MTX (20 mg) into a 20 mL volumetric flask 
with DMSO to give a final concentration of 1 mg/mL. 
The stock solution was stored at 2-8 °C, protected from 
light, and further diluted with mobile phase (for the LC 
analysis) or with 0.1 M NaOH (for the UV 
spectrophotometric measurements) to yield working 
solutions containing 1, 5, 10, 15, 20 and 30μg/mL. 
Finally, samples for LC analysis were filtered through a 
0.45 μm membrane filter (Millipore) before injection into 
the chromatographic system.  
2.4. Preparation of Unloaded and MTX-Loaded 
Chitosan Nanoparticles  
Chitosan-based NPs were prepared following the 
ionic gelation technique [11], which is based on the 
ionotropic complexation of CS with TPP anions. To the 
standard procedure, some modifications were included, 
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such as the incorporation of a biocompatible and pH-
sensitive amino acid-based surfactant as a NP modifier 
[20]. The surfactant used is derived from N?, N?-
dioctanoyl lysine, has an inorganic sodium counterion 
(77KS) and was synthesized as previously described 
[21]. 77KS was included in the complexation process 
and the NPs were prepared with a selective 
CS:TPP:77KS ratio of 5:1:0.5 (w/w/w).  
MTX-loaded CS NPs (MTX-CS-NPs) were prepared 
as follows: firstly, a MTX solution (at 0.1% w/v) was 
added to a premixed TPP and 77KS solution (both at 
0.1%, w/v, with a TPP:77KS ratio equal to 1:0.5, w/w). 
MTX-NPs were then prepared by dropwise addition of 
this premixed solution (TPP:77KS:MTX, with a final 
ratio of 1:0.5:1, w/w/w) to CS (0.1%, w/v) previously 
dissolved in acetic acid solution (1%, v/v). The pH of 
the CS solution was adjusted to 5.5 with 1 M NaOH 
[22]. The NPs were produced at room temperature and 
dark conditions, under constant magnetic stirring (1000 
rpm) for 20 min. Unloaded CS-NPs were prepared 
according to the procedure previously described, 
omitting the drug.  
2.5. Validation of the RP-LC and UV 
Spectrophotometric Methods 
The methods were validated by determinations of 
the following parameters: specificity, linearity, range, 
precision, accuracy, limit of detection (LOD), limit of 
quantification (LOQ) and robustness, following the 
International Conference on Harmonisation (ICH) 
guideline [23]. 
Specificity was evaluated by analyzing unloaded 
CS-NPs, containing all the components of the 
formulation, except the drug. The samples were diluted 
with methanol and sonicated for 15 min in order to 
dissolve the NPs and extract any interference from 
them. The resulting solution was further diluted in 
mobile phase and injected into the LC system to 
investigate the ingredient interference on the selectivity 
of the MTX separation. Moreover, it was evaluated a 
sample of MTX-loaded NPs at a drug concentration of 
15 ?g/mL, following the same procedure described 
above. Then, the purity of MTX peak was determined 
using a PDA detector. For the UV method, samples 
with and without drug were diluted with 0.1 M NaOH 
after the extraction procedure, and absorption spectra 
were compared in order to verify the occurrence of any 
interference in wavelength of MTX maximum 
absorption.  
The linearity was determined by constructing three 
independent analytical curves, each one with six 
concentrations of MTX, including the LOQ, in the range 
of 1 - 30 μg/mL, prepared in mobile phase or 0.1M 
NaOH for the LC or UV spectrophotometric method, 
respectively. Three replicate analyses of each sample 
were made to verify the repeatability of the responses. 
The peak areas of the chromatograms or the 
absorptions values were plotted against the respective 
concentrations of MTX to obtain the analytical curve. 
The results were subjected to regression analysis by a 
least-squares method to calculate calibration equation 
and correlation coefficient. The limit of detection (LOD) 
and the limit of quantification (LOQ) were calculated, as 
defined by ICH [23] using the mean values of three 
independent analytical curves, where the factors 3.3 
and 10 for the detection and quantification limits, 
respectively, were multiplied by the ratio from the 
standard deviation of the intercept and the slope.  
The precision of the methods was determined by 
the repeatability and the intermediate precision. 
Repeatability was examined by analyzing six MTX-CS-
NPs samples at the same concentration (15 μg/mL), on 
the same day, and under the same experimental 
conditions. Before analyses, samples were diluted and 
extracted as described for the specificity test. The 
intermediate precision was assessed by carrying out 
the analysis on three different days (inter-days), and 
also by other analysts performing the analysis in the 
same laboratory (between-analysts). Precision was 
expressed as relative standard deviation (RSD) and the 
results must be less than 2%. 
Accuracy was evaluated assaying, in triplicate, 
samples of known concentrations of MTX-CS-NPs (10 
μg/mL) spiked with three different concentrations of 
standard solution (2, 5 and 8 μg/mL) at three different 
levels (lower, medium, and upper concentration), giving 
sample solutions with concentrations of 12, 15 and 18 
μg/mL, equivalent to 80, 100 and 120% of the nominal 
analytical concentration, respectively. The accuracy 
was calculated as the percentage of drug recovered 
from the sample (recovery %), which was calculated 
from differences between the responses obtained for 
spiked and unspiked solutions. 
The robustness of an analytical procedure refers to 
its ability to remain unaffected by small and deliberate 
variations in method parameters and provides an 
indication of its reliability for routine analysis. 
Therefore, robustness was determined by analyzing 
MTX-CS-NPs samples (15 μg/mL) under a variety of 
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conditions with small variations of the method para-
meters. For LC method, the variations were performed 
in the flow rate, wavelength, buffer pH and proportion 
of acetonitrile, while for UV spectrophotometric method, 
changes were made in the wavelength and in the 
sonication time necessary to extract the drug from NPs. 
The system suitability test was also carried out for 
the RP-LC method to evaluate the reproducibility of the 
system for the analysis to be performed, using six 
replicates injections of both reference and sample 
solutions containing 15 μg/mL of MTX. The parameters 
measured were peak area, retention time, theoretical 
plates and tailing factor (peak symmetry). 
2.6. Analysis of MTX Content into the Formulations 
For the quantitative analysis, the drug was extracted 
from the NPs with methanol, followed by sonication for 
15 min. Then, the samples were diluted with mobile 
phase or 0.1 M NaOH for the LC or UV spectro-
photometric measurements, respectively, to reach up a 
concentration of 15 ?g/mL. Finally, the amount of drug 
was calculated against the reference substance. The 
results obtained were statistically compared by 
Student´s t test and ANOVA in order to verify the 
similarity of the experimental values and, thus, to 
determine the equivalence of both methods for the 
assessment of MTX in CS-based NPs.  
2.7. Drug Entrapment Efficiency 
The entrapment efficiency (EE%) was estimated as 
being the difference between the total concentration of 
MTX found in the NP suspension after the complete 
dissolution in methanol and the concentration of drug in 
the ultrafiltrate after separation of the NPs by 
ultrafiltration/centrifugation technique using Amicon 
Ultra-0.5 Centrifugal Filters (10,000 Da MWCO, 
Millipore). EE% was calculated by the difference 
between the total and free MTX concentrations 
determined in the NPs (drug content) and in the 
ultrafiltrate, respectively, using the LC method.  
2.8. In Vitro MTX Release Assay 
In vitro release evaluations from pH-sensitive MTX-
loaded CS-NPs were carried out for 8 h in phosphate 
buffer saline (PBS) at pH 7.4 and 5.4. An aliquot of 
NPs was placed in a dialysis bag (Sigma-Aldrich, 
14000 MWCO) and suspended in 50 mL of PBS at 
37ºC under gentle magnetic stirring (100 rpm). At pre-
determined intervals, 2 mL of medium was withdrawn 
and replaced with an equal volume of fresh medium. 
The amount of MTX released was estimated by the 
RP-LC method. In order to assess the influence of the 
medium used, the method was co-validated for linearity 
and range using the release medium (PBS pH 7.4 or 
5.4) as diluent.  
2.9. UV Degradation Study 
The system for irradiation of the samples consisted 
of a shortwave UV mercury lamp as UVC radiation 
source (? = 254 nm), installed inside a photo stability 
chamber. Photodegradation was induced by exposing 
the samples (MTX-CS-NPs; CS:TPP:77KS, 5:1:0.5 
w/w/w), in a covered transparent container, to the UV 
radiation for 6 h. Every hour, samples were taken from 
the chamber; the drug was extracted from NPs as 
previously described, and then analyzed by LC to 
determine the content of MTX. 
The photolytic degradation kinetics of MTX-loaded 
NPs was calculated by the graphic method, through 
which it was possible to determine the degradation 
constant. Zero order, first order and second order 
graphics were drawn by plotting the drug residual 
content versus time, ln of drug residual content versus 
time and 1/drug residual content versus time, 
respectively. The definition of kinetic order was 
performed by calculation of the correlation coefficient of 
each curve. The graph with the best fit was then 
considered to establish the kinetic order. Finally, half-
life (t1/2) and t90 value (time for 10% decomposition) 
were determined from the k-value [24]. 
2.10. Statistical Analyses 
Statistical analyses were performed using Student´s 
t test or one-way analysis of variance (ANOVA) to 
determine the differences between the datasets, 
followed by Tukey’s post-hoc test for multiple 
comparisons using SPSS® software (SPSS Inc., 
Chicago, IL, USA). p < 0.05 was considered significant.  
3. RESULTS AND DISCUSSION 
3.1. Optimization of the Methods 
Chromatographic and UV spectrophotometric 
methods have been widely used for many analytical 
purposes and, motivated by the growing development 
of nanotechnology, these analytical tools started to be 
applied for drug assay in nanomaterial-based products 
[25-27]. This innovative type of pharmaceuticals usually 
contains a complex matrix, including polymers and 
surfactants. In this way, the current analytical 
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methodology for the conventional pharmaceutical 
formulations may not be suitable for the analysis 
intended and, thus, specific analytical methods must be 
carefully developed and validated to demonstrate its 
suitability. For that reason, in this work, two analytical 
methods were proposed as important and appropriate 
tools to determine the antitumor drug MTX in pH-
sensitive polymeric NPs.  
The experimental conditions were adjusted in order 
to obtain efficient routine analysis. To achieve the best 
performance of the RP-LC method, the mobile phase 
was optimized to provide sufficient selectivity and 
sensitivity in a short separation time. Phosphate buffer 
resulted in high sensitivity and better separation in 
comparison with acidic aqueous solutions (ultrapure 
water acidified with phosphoric acid or glacial acetic 
acid). Even though acidic pH used to diminish the 
absorbance values of MTX [28], the pH selected was 
3.2 because MTX (pKa 3.8, 4.8 and 5.6) can be found 
mostly in its undissociated form under this condition 
[29]. The LC technique is very sensitive and, thus, a 
reduced absorbance is not critical for the good 
performance of the methodology. Moreover, the 
literature reports the quantification of MTX, in both 
pharmaceutical products and biological matrices, using 
mixtures of aqueous buffer at pH values ranging from 
2.5 to 6.7 [28]. The acetonitrile was chose as organic 
phase since it resulted in short analysis time, with 
improved peak symmetry (about 1.17). Different 
proportions of mobile phase were tested, and the one 
with 86:14, v/v (buffer-acetonitrile) was selected due to 
the fast elution of the analyte, achieved with acceptable 
chromatographic parameters. The main advantage of 
this method was that the total run time was set as only 
8 min, allowing a fast determination of the drug, with 
low consumption of organic solvents.  
Considering that simple methods are more 
affordable for the routine analysis of pharmaceuticals, a 
UV spectrophotometric method was also developed 
and further optimized for the detection wavelength and 
diluent. To choose the wavelength that allows the 
maximum absorption of MTX, scans were conducted in 
a range of 200–600 nm, and the set wavelength was 
the same of the LC method (303 nm). Likewise, the 
diluent selected (0.1 M NaOH) was simple, provide 
great sensitivity and did not show any interference or 
absorption within the drug. MTX strongly absorbs at 
UV-Vis range, due to the presence of the chromophore 
heteroaromatic pterine, and it was reported that the 
maximum absorbance is dependent on the pH. The 
highest molar extinction of MTX is obtained at neutral 
pH, while acidic conditions use to reduce the absorb-
ances [28]. This behavior justifies the selection of a 
NaOH solution as diluent, which gave good sensitivity 
to the analytical procedure. Finally, the possible 
precipitation of the sample after its redispersion in 
mobile phase or 0.1 M NaOH solution was also 
evaluated before analysis. No precipitation of any 
component of the formulation was observed, probably 
because of their low concentration in the final sample. 
3.2. Validation of the Methods 
Regarding the specificity evaluation, the chromato-
grams (Figure 1) and absorption spectra (Figure 2) 
showed that both LC and UV spectrophotometric 
methods, respectively, are specific, without any 
interference or overlaps of the components of NPs with 
the MTX response at the detection wavelength of 303 
nm. In order to confirm this absence of interference in 
the LC method, a peak-purity evaluation using the PDA 
detector was carried out. These analyses showed that 
the MTX peak was free from any co-eluting peak 
(impurities and/or excipients), with values of peak purity 
index higher than 0.9999.  
 
Figure 1: Representative RP-LC chromatograms obtained 
during the evaluation of the method specificity. Trace (1) 
represents the unloaded-NPs, (2) the reference solution of 
MTX (15 μg/mL) and (3) the MTX-CS-NPs (15 μg/mL).  
 
Figure 2: Absorption spectra obtained by UV 
spectrophotometric method during the evaluation of its 
specificity. Trace (1) represents the unloaded-NPs, (2) the 
MTX-CS-NPs (15 μg/mL) and (3) the reference solution of 
MTX (15 μg/mL).  
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The analytical curves constructed for MTX were 
found to be linear for both methods in the 1 - 30 μg/mL 
range. The linear regression equations obtained by the 
least-square method and the values of the correlation 
coefficient (y = 60463.13x + 8207.2, r = 0.9999, for RP-
LC; and y = 0.044205x + 0.001928, r = 0.9999, for UV 
spectrophotometry; where x is concentration and y is 
the peak absolute area or absorbance) indicated the 
linearity of the analytical curves for both methods. 
Moreover, the validity of the assays was verified by 
analysis of variance (ANOVA). This revealed that the 
regression equations were linear (Fcalculated = 39,578.96 
> Fcritical = 4.75, p < 0.05, for LC method; and Fcalculated = 
17,325.12 > Fcritical = 4.75, p < 0.05, for UV 
spectrophotometric method) with no linearity deviation 
(Fcalculated = 0.31 < Fcritical = 3.26; p > 0.05, for LC 
method; and Fcalculated = 0.37 < Fcritical = 3.26; p > 0.05, 
for UV spectrophotometric method). The LOD and LOQ 
were calculated by using the mean of the slope and the 
standard deviation of intercept of three independent 
curves. The obtained values for LOD and LOQ were 
0.37 and 1.25 μg/mL, respectively, for LC method, and 
0.53 and 1.75 μg/mL, respectively, for UV 
spectrophotometric method. The LOQ evaluated in an 
experimental assay, with a precision lower than 5% 
and accuracy within ± 5%, was found to be 1 μg/mL for 
both methods. 
The precision, evaluated as repeatability of the 
methods, was studied by calculating the relative 
standard deviation (RSD) for six determinations of 
MTX-CS-NPs samples, performed on the same day 
and under the same experimental conditions. The 
intermediate precision was assessed by analyzing two 
samples of MTX-loaded NPs on three different days 
(inter-day) and by three different analysts (between-
analyst). The results are given in Table 1 and the 
obtained RSD values are lower than the acceptance 
criterion of 2%. Regarding the accuracy evaluation, 
good recoveries (98–102%) were obtained (Table 2), 
demonstrating that both methods are accurate within 
the desired range. 
Table 2: Accuracy Data of RP-LC and UV 
Spectrophotometric Methods for MTX in 
Samples of Chitosan-Based NPs 
RP-LC UV spectrophotometry 
Level 
(?g/mL) Recovery 
(%) 
RSD
* 
(%) 
Recovery 
(%) 
RSD
* 
(%) 
12 99.36  0.47 100.59  0.55 
15 99.35 0.12 98.83 0.80 
18 99.47  0.01 98.02  0.60 
* RSD = relative standard deviation. 
 
The robustness was evaluated by making 
alterations on the experimental range of some of the 
most important parameters of the methods. It was 
studied the effects of performing variations on the 
wavelength (± 2 nm) for both methods, on the 
sonication time (± 3 min) for UV spectrophotometric 
method, and on the buffer solution pH (± 0.2), % of 
acetonitrile (± 2%) and flow rate (± 0.1 mL/min), for LC 
Table 1: Repeatability
? 
and Intermediate Precision
§
 Data of RP-LC and UV Spectrophotometric Methods for MTX in 
Samples of Chitosan-Based NPs 
 RP-LC UV spectrophotometry 
 Recovery ± SD (%)  RSD*
 
(%) Recovery ± SD (%)  RSD
* 
(%) 
Intra-day (n = 6) 101.23 ± 0.8402 0.83 103.61 ± 1.68 1.62 
Inter-day     
Day 1 (n = 3) 100.90 ± 0.0048 0.48 100.34 ± 0.0077 0.76 
Day 2 (n = 3) 99.48 ± 0.0148 1.49 102.19 ± 0.01 0.98 
Day 3 (n = 3) 102.43 ± 0.0043 0.42 103.19 ± 0.0163 1.58 
Mean (n = 9) 100.94 ± 0.0148 1.46 101.91 ± 0.0145 1.42 
Between-analysts     
Analyst 1 (n = 3) 100.67 ± 0.0061 0.60 100.34 ± 0.0077 0.76 
Analyst 1 (n = 3) 102.14 ± 0.0070 0.69 103.19 ±0.0163 1.58 
Analyst 1 (n = 3) 101.35 ± 0.045 0.45 104.14 ± 0.0192 1.84 
Mean (n = 9) 101.39 ± 0.0074 0.73 102.56 ± 0.0198 1.93 
? intra-day 
§ inter-day and between-analysts 
* RSD = relative standard deviation 
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method. The analyses of reference and sample 
solutions containing 15 ?g/mL of MTX were carried out 
in triplicate changing only one parameter at a time. The 
results of experimental range of variables evaluated 
were within the acceptable deviation (RSD < 2%), 
which demonstrated that there were no significant 
changes in the chromatographic pattern and/or on 
assay data when small modifications were made in the 
experimental environment, thus showing the methods 
to be robust under the conditions tested.  
Finally, a system suitability test was carried out to 
evaluate the adequability and reproducibility of the LC 
system for the analysis to be performed. The RSD 
values calculated for the retention time, tailing factor 
and peak area were lower than 0.56, 0.62 and 1.41%, 
respectively. The number of theoretical plates was 
about 9405.65, with RSD < 1.76%. The experimental 
results show that the parameters tested were within the 
acceptable range (RSD < 2.0%), indicating that the 
system is suitable for the analysis intended.  
3.3. Application of the Validated Methods 
In order to demonstrate the applicability of both 
methods, pH-sensitive MTX-loaded NPs were assayed 
(six batches) using the conditions optimized and 
validated for each methodology (Table 3). The 
determination of drug content in sample solutions 
showed acceptable results (mean recovery of 105.29% 
and 105.62% for RP-LC and UV spectrophotometric 
methods, respectively). RSD values were lower than 
2.0% from triplicate analysis of each sample, which 
indicates precise analytical methods. The experimental 
values of the two methods were compared statistically 
by the Student's t test and by ANOVA, showing non-
significant differences (Calculated value < Critical 
value; p > 0.05). 
It is of great importance the determination of the 
amount of drug that is really entrapped into the 
nanocarrier. Therefore, it is necessary to have a 
precise and accurate methodology to perform this 
assessment. In this line, the proposed RP-LC method 
was also applied to determine the EE% of MTX in NPs, 
and the mean value obtained was 38.37%. 
In addition, the sensitivity of the LC method allowed 
the performance of in vitro release studies of MTX from 
the NPs as a function of pH. First of all, analytical 
curves were constructed using PBS pH 7.4 and 5.4 as 
diluents. It was observed that changing the sample 
diluent from mobile phase to PBS did not modify the 
chromatographic performance and/or altered the 
quantification power of the validated LC method. Linear  
Table 3: Comparison between the RP-LC and UV 
Spectrophotometric Methods Applied for the 
Analysis of MTX in Samples of Chitosan-Based 
NPs 
RP-LC UV spectrophotometry 
Sample Recovery 
(%) 
RSD
* 
(%) 
Recovery 
(%) 
RSD
* 
(%) 
1 105.11 0.52 104.58 0.17 
2 106.81 0.12 106.39 0.51 
3 103.34 0.21 105.16 0.09 
4 105.24 0.13 104.13 0.09 
5 105.21 0.02 106.45 0.08 
6 106.02 0.24 106.97 0.26 
Mean 105.29 1.10 105.62 1.09 
Statistical 
analysis 
Critical value § Calculated value 
Student´s t test 2.23 0.63 
ANOVA 4.96 0.24 
* RSD = relative standard deviation. 
§ significance level p = 0.05 
 
regression equations were obtained by the least-
square method and the values of the correlation 
coefficient (y = 59621.32x + 3766.19 r = 0.9998, for 
PBS pH 7.4; and y = 62270.37x + 1833.55, r = 0.9999, 
for PBS pH 5.4; where x is concentration and y is the 
peak absolute area) indicated the linearity of both 
curves, independently of the pH. The cumulative 
amounts of MTX released from MTX-CS-NPs are 
shown in Figure 3. Both at physiological and acidic 
conditions, the drug showed an initial burst release, 
following by a sustained release up to 8 h. The amount 
of drug released at pH 5.4 was higher than at pH 7.4 in 
each schedule time. This behavior showed the pH-
dependent properties of the formulation.  
Finally, the LC method was successfully applied to 
assess the degradation profile of MTX entrapped in the 
NPs after exposure to UVC radiation. The chromato-
gram obtained after 6 h exposure of NPs to the 
radiation is presented in Figure 4. It was shown that 
~90% of the drug degraded under the test conditions, 
and four detectable eluting degradation products were 
observed. The MTX peak purity index was determined, 
providing acceptable value. Altogether, these results 
indicated that the LC method might have a stability-
indicating capability, which evidently has to be 
confirmed by additional forced degradation studies. On 
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the other hand, the graphics of zero order, first order 
and second order models were constructed for 
modeling the kinetics of MTX degradation in NPs after 
UVC exposure. The graphic with the best correlation 
coefficient was considered to establish the kinetic order 
and, thus, it was stated that the degradation profile of 
MTX in the nanostructure was according to zero order 
kinetics (r = 0.9786). The degradation constant was 
determined by the graphic equation and the value 
obtained was 0.0416 ?g mL min-1. The half-life (t1/2) 
was determined from the k-value and the result 
obtained was very close to the experimental values. 
The calculated t1/2 was 180.3 min, whereas ~60% of 
degradation occurs in 240 min. Moreover, the t90 value 
was estimated as 36.06 min under the tested 
conditions. 
 
Figure 3: In vitro cumulative release profiles of MTX from 
CS-NPs in PBS pH 7.4 and 5.4. Results are expressed as 
mean ± standard error of three independent experiments. 
Statistical analyses were performed by ANOVA followed by 
Tukey´s multiple comparison test. *significantly different from 
PBS pH 7.4 (p < 0.05). 
 
Figure 4: Representative RP-LC chromatogram of MTX-CS-
NPs after 6 h exposure to UVC radiation. Peak (1) 
corresponds to MTX, and peaks (2), (3), (4) and (5) 
correspond to photodegradation products of MTX. 
4. CONCLUSIONS 
The results of the validation studies show that the 
RP-LC and UV spectrophotometric methods are 
specific, linear, precise and accurate. Both 
methodologies were successfully applied for assay 
MTX in pH-sensitive CS-based NPs, without any 
interference of their complex matrix composed of 
polymers and surfactants. Moreover, considering the 
efficiency and high-resolution of the chromatographic 
technique, the proposed RP-LC method was used to 
assess MTX entrapment efficiency, as well as to 
determine the in vitro MTX release profile and the 
photolytic degradation kinetics of the encapsulated 
drug. Altogether, the results proved that the validated 
methods could be suitable approaches to quantify MTX 
in complex matrices of nanotechnology-based 
polymeric formulations. Finally, it is worth mentioning 
that the availability of reliable analytical methodologies 
can contribute to improve the quality and to ensure the 
therapeutic efficacy of the new formulations that have 
been developed.  
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